Document Detail


Experimental human endotoxemia is associated with depression of load-independent contractility indices: prevention by the lipid a analogue E5531.
MedLine Citation:
PMID:  15364767     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
OBJECTIVE: To evaluate the efficacy of a novel lipopolysaccharide (LPS) antagonist, E5531, in blocking LPS-induced cardiac responses including myocardial depression (as assessed by relatively load-independent echocardiographic indices of contractility) in a human model of experimental endotoxemia. DESIGN: Randomized, prospective, placebo-controlled, double-blind trial. SETTING: ICU procedure room. PARTICIPANTS: Thirty-two healthy, male volunteers. INTERVENTIONS: Administration of LPS (4 ng/kg) and either a placebo or one of four sequential doses of E5531 (100 microg, 250 microg, 500 microg, or 1,000 microg) followed by volumetric echocardiography before and during 4-L saline solution infusion (3 L over 3 h, followed by 1 L over 2 h). RESULTS: In addition to the generation of a hyperdynamic circulation throughout the study period, administration of LPS resulted in a biphasic contractility response. Ejection fraction (EF), rate-corrected mean velocity of circumferential fiber shortening (Vcfc), peak systolic BP (SBP)/end-systolic volume index (ESVI) ratio, and end-systolic pressure (Pes)/ESVI ratio increased at the 3-h post-LPS assessment, compared to a control group of subjects receiving only similar amounts of saline solution (minimum p < 0.001). End-systolic myocardial wall stress (sigmaes)/ESVI ratio, one of the most load independent of the contractility indices, was unchanged. At 5 h after endotoxin, EF, Vcfc, SBP/ESVI, Pes/ESVI, and sigmaes/ESVI were all decreased (minimum p < 0.01), indicating myocardial depression. When present, early (3 h after LPS), apparent enhancement of myocardial contractility and later (5 h after LPS) myocardial depression were substantially blunted by administration of E5531 (minimum p < 0.025), typically in a concentration-dependent manner. CONCLUSIONS: Endotoxin generates significant myocardial depression when measured using highly load-independent indices of cardiac contractility. E5531 is a potent inhibitor of the early hyperdynamic cardiovascular and later myocardial depression response seen in experimental human endotoxemia.
Authors:
Anand Kumar; Eugene Bunnell; Melvyn Lynn; Ramon Anel; Kalim Habet; Alex Neumann; Joseph E Parrillo
Related Documents :
2923517 - Right and left ventricular performance during and after abdominal aortic aneurysm repair.
7573507 - Endotoxin-induced left ventricular depression is blocked by nitrogen mustard or dimethy...
1000777 - Evaluation of the force-frequency relationship as a descriptor of the inotropic state o...
903897 - An x-ray diffraction study of the cross-circulated canine heart.
10789697 - Augmentation of somato-sympathetic reflex in the ischemic hindlimb of anesthetized rats.
21118567 - Daily steps are low year-round and dip lower in fall/winter: findings from a longitudin...
Publication Detail:
Type:  Clinical Trial; Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Chest     Volume:  126     ISSN:  0012-3692     ISO Abbreviation:  Chest     Publication Date:  2004 Sep 
Date Detail:
Created Date:  2004-09-14     Completed Date:  2004-11-02     Revised Date:  2007-11-15    
Medline Journal Info:
Nlm Unique ID:  0231335     Medline TA:  Chest     Country:  United States    
Other Details:
Languages:  eng     Pagination:  860-7     Citation Subset:  AIM; IM    
Affiliation:
Section of Critical Care Medicine, Health Sciences Centre, GE706, 820 Sherbrook St, Winnipeg, MB, Canada, R3A 1R9. akumar61@yahoo.com
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Adolescent
Adult
Cardiac Output, Low / drug therapy*,  physiopathology
Dose-Response Relationship, Drug
Double-Blind Method
Endotoxemia / drug therapy*
Escherichia coli
Hemodynamics / drug effects,  physiology
Humans
Intensive Care Units
Lipid A / analogs & derivatives*,  therapeutic use*
Lipopolysaccharides / toxicity
Male
Myocardial Contraction / drug effects*,  physiology
Chemical
Reg. No./Substance:
0/E 5531; 0/Lipid A; 0/Lipopolysaccharides

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Assessment of physiologic variables and subjective comfort under different levels of pressure suppor...
Next Document:  Evaluation of a modified percutaneous tracheostomy technique without bronchoscopic guidance.